高脂血症性急性胰腺炎的临床特征及其与脂代谢的关系

安文慧; 杨婧; 何旭昶; 任蓓蓓; 杨秋瑾; 郑杰

doi:10.3969/j.issn.1001-5256.2020.04.030

高脂血症性急性胰腺炎的临床特征及其与脂代谢的关系

DOI: 10.3969/j.issn.1001-5256.2020.04.030

1. 昆明医科大学第二附属医院消化内科
2. 昆明医科大学第二附属医院肝胆外科

基金项目:

科技人才和平台计划(2019IC034)；

详细信息

中图分类号: R576
计量
- 文章访问数: 1435
- HTML全文浏览量: 60
- PDF下载量: 242
- 被引次数: 5
出版历程
- 收稿日期: 2019-11-28
- 出版日期: 2020-04-20

Clinical features of hyperlipidemic acute pancreatitis and their association with lipid metabolism

Department of Gastroenterology,The Second Affiliated Hospital of Kunming Medical University

Research funding:

摘要

摘要: 目的探讨高脂血症性急性胰腺炎（HLAP）患者的临床特征,以及脂代谢谱与HLAP的关系。方法选取2017年9月-2019年9月昆明医科大学第二附属医院消化内科收治的61例HLAP患者（HLAP组）与同期77例非高脂血症性急性胰腺炎患者（NONHLAP组）。分析2组患者的临床特点,包括基线资料、实验室指标、病情分级、合并症、严重程度评分等。符合正态分布的计量资料2组间比较采用t检验;不满足正态分布的计量资料2组间比较采用Mann-Whitney U检验。计数资料2组间比较采用χ2检验。采用多因素二分类logistic回归分析HLAP的独立危险因素,Z检验比较受试者工作特征曲线下面积（AUC）。结果 2组间年龄（t=-6. 125）,BMI（t=4. 125）,合并感染（χ2=4. 364）、脂肪肝（χ2=50. 567）、糖尿病（χ2=28. 408）,hs-CRP（Z=-2. 456）,WBC（t=2. 652）,中性粒细胞（t=2. 232）,淋巴细胞（Z=-2. 339）,D二聚体（Z=-8. 6...
- 高脂血症性急性胰腺炎 /
- 脂代谢障碍 /
- 载脂蛋白类 /
- 脂蛋白类
Abstract: Objective To investigate the clinical features of patients with hyperlipidemic acute pancreatitis( HLAP) and the association between lipid metabolism profile and HLAP. Methods A total of 61 patients with HLAP who were treated in Department of Gastroenterology,The Second Affiliated Hospital of Kunming Medical University,from September 2017 to September 2019 were enrolled as HLAP group,and77 patients with non-hyperlipidemic acute pancreatitis were as non-HLAP group. The clinical features of the two groups were analyzed,including baseline data,laboratory markers,disease grade,comorbidities,and severity score. The t-test was used for comparison of normally distributed continuous data between groups,and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups. The chi-square test was used to for comparison of categorical data between groups. A multivariate binary logistic regression analysis was used to investigate the independent risk factors for HLAP,and the Z test was used for comparison of the area under the ROC curve( AUC). Results There were significant differences between the two groups in age( t =-6. 125,P < 0. 05),body mass index( t = 4. 125,P < 0. 05),infection( χ2= 4. 364,P < 0. 05),fatty liver disease( χ2= 50. 567,P < 0. 05),diabetes( χ2=28. 408,P < 0. 05),high-sensitivity C-reactive protein( Z =-2. 456,P < 0. 05),white blood cell count( t = 2. 652,P < 0. 05),neutrophils( t = 2. 232,P < 0. 05),lymphocytes( Z =-2. 339,P < 0. 05),D-dimer( Z =-8. 601,P < 0. 05),fasting blood glucose( Z =-4. 416,P < 0. 05),uric acid( t = 4. 644,P < 0. 05),total cholesterol( Z =-8. 937,P < 0. 05),triglyceride( Z =-8. 87,P <0. 05),low-density lipoprotein cholesterol( Z =-7. 972,P < 0. 05),non-high-density lipoprotein( Z =-9. 085,P < 0. 05),apolipoprotein B( Z =-3. 244,P < 0. 05),systemic inflammatory response syndrome score( Z =-2. 817,P < 0. 05),and Modified Early Warning Score( Z =-2. 226,P < 0. 05). Triglyceride( odds ratio [OR]= 0. 675,95% confidence interval [CI]: 0. 484-0. 943,P =0. 021) and non-high-density lipoprotein( OR = 0. 320,95% CI: 0. 164-0. 624,P = 0. 001) were independent risk factors for HLAP.Non-high-density lipoprotein( AUC = 0. 951,sensitivity = 100%,specificity = 88. 31%,95% CI: 0. 901-0. 981,SE = 0. 020,Youden index = 0. 883) and triglyceride( AUC = 0. 940,sensitivity = 95. 08%,specificity = 81. 82%,95% CI: 0. 887-0. 974,SE = 0. 018,Youden index = 0. 769) had high diagnostic efficiency. Non-high-density lipoprotein with a cut-off value of > 4. 55 mmol/L had the highest diagnostic value. Conclusion HLAP often occurs in the population with metabolic syndrome,with a younger age of onset and more severe inflammatory response. Non-high-density lipoprotein has a high value in the diagnosis of HLAP,which provides a new idea for guiding clinical treatment.
- hyperlipidemia acute pancreatitis /
- lipid metabolism disorders /
- apolipoproteins /
- lipoproteins

HTML全文

参考文献(14)

[1] HUANG W,WINDSOR JA. Fulminant or early severe acute pancreatitis is overlooked by classifications of severity[J].Crit Care Med,2017,45(7):e744-e745.

[2] HUANG YX,JIA L,JIANG SM,et al. Incidence and clinical features of hyperlipidemic acute pancreatitis from Guangdong,China:A retrospective multicenter study[J]. Pancreas,2014,43(4):548-552.

[3] ZHANG N,ZHANG HY,GUO XH,et al. Meta-analysis of the characteristics of the etiology of acute pancreatitis in China in the past ten years[J/CD]. Chin J Digest Med Imageol(Electronic Edition),2016,6(2):71-75(in Chinese)．张娜，张海燕，郭晓红，等．中国近十年急性胰腺炎病因变化特点的Meta分析[J/CD]．中华消化病与影像杂志(电子版)，2016,6(2):71-75.

[4] WANG XP,LI ZS,YUAN YZ,et al. Chinese guidelines for the diagnosis and treatment of acute pancreatitis(2013,Shanghai)[J]. J Clin Hepatol,2013,29(9):656-660.(in Chinese)王兴鹏，李兆申，袁耀宗，等．中国急性胰腺炎诊治指南(2013年，上海)[J]．临床肝胆病杂志，2013,29(9):656-660.

[5] YEH JH,CHEN JH,CHIU HC. Plasmapheresis for hyperlipidemic pancreatitis[J]. J Clin Apher,2003,18(4):181-185.

[6] MA JC,BAO ZJ. Research progress on the pathogenesis of hyperlipidemic acute pancreatitis[J]. Int J Dig Dis,2017,37(1):24-27.(in Chinese)马江辰，保志军．高脂血症性急性胰腺炎发病机制的研究进展[J]．国际消化病杂志，2017,37(1):24-27.

[7] PACKARD CJ. Determinants of achieved LDL cholesterol and“Non-HDL”cholesterol in the management of dyslipidemias[J]. Curr Cardiol Rep,2018,20(8):60.

[8] RAMJEE V,SPERLING LS,JACOBSON TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification:Do the math[J]. J Am Coll Cardiol,2011,58(5):457-463.

[9] MASSON W,LOBO M,SINIAWSKI D,et al. Impact of lipidlowering therapy on mortality according to the baseline NonHDL cholesterol level:A meta-analysis[J]. High Blood Press Cardiovasc Prev,2019,26(4):263-272.

[10] YADAV D,PITCHUMONI CS. Issues in hyperlipidemic pancreatitis[J]. J Clin Gastroenterol,2003,36(1):54-62.

[11] SUDHOP T. Inhibition of intestinal cholesterol absorption by ezetimibe in humans[J]. Circulation,2003,106(15):1943-1948.

[12] CAO X,WANG HM,DU H,et al. Early predictors of hyperlipidemic acute pancreatitis[J]. Exp Ther Med,2018,16(5):4232-4238.

[13] WANG BB,LIAO SY,MA J,et al. Analysis of clinical characteristics of acute pancreatitis with different etiology[J]. J Clin Hepatol,2018,34(1):147-151.(in Chinese)王蓓蓓，廖山婴，马娟，等．不同病因急性胰腺炎的临床特点分析[J]．临床肝胆病杂志，2018,34(1):147-151.

[14] LI HQ,LIU W,TANG J,et al. Evaluation value of triglyceride,C-reactive protein and procalcitonin on the severity and prognosis of hyperlipidemic acute pancreatitis[J]. Clin J Med Offic,2019,47(9):923-925.(in Chinese)历海清，刘卫，唐郡，等．甘油三酯、C反应蛋白、降钙素原对高脂血症性急性胰腺炎病情严重程度及预后评估价值[J]．临床军医杂志，2019,47(9):923-925.

施引文献

期刊类型引用(5)

1.	康志龙，周益民，宋燕州，张昆，苏一男，魏文平，赵新，李志伟. 靶向免疫治疗联合经肝动脉灌注化疗治疗不可切除肝细胞癌的临床效果及转化治疗的影响因素. 中国医学创新. 2025(01): 47-51 . 百度学术
2.	许海明，胡永奎，梁平，钟腾猛，陆炳站. 中晚期肝癌患者经动脉化疗栓塞治疗后短期效果及长期预后的影响因素分析. 大医生. 2025(06): 27-31 . 百度学术
3.	彭林辉，陈涛，徐云修修，王捷，陈捷，李永，黄拼搏，钟国平，陈茜，叶聪婷，陈亚进. mFOLFOX7方案全身化疗联合卡瑞利珠单克隆抗体和阿帕替尼治疗肝细胞癌合并Vp4型门静脉癌栓的疗效. 中华消化外科杂志. 2024(02): 265-271 . 百度学术
4.	李洁，李瑞娟，鲁志兵，曾筱怡. 肝动脉灌注化疗联合程序性死亡受体1抗体及仑伐替尼治疗晚期肝癌合并门静脉癌栓的效果. 中国当代医药. 2024(26): 43-46+51 . 百度学术
5.	黄乾鑫，神斌，肖晋昌，高志康，吕墩涛，李艳，徐浩，张庆桥. 载药微球经导管动脉化疗栓塞术联合肠系膜上动脉灌注化疗治疗肝细胞癌合并门静脉癌栓的效果分析. 临床肝胆病杂志. 2024(12): 2457-2463 . 本站查看